RecruitingPhase 2NCT07415954

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

Sponsor

Novo Nordisk A/S

Enrollment

270 participants

Start Date

Apr 17, 2026

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus, Type 2

Summary

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NNC0662-0419, a drug called Placebo, and others for people with diabetes mellitus, type 2. The study is currently recruiting participants at 63 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNNC0662-0419

NNC0662-0419 will be administered subcutaneously.

DRUGSemaglutide

Semaglutide will be administered subcutaneously.

DRUGPlacebo

Placebo will be administered subcutaneously.

Locations(63)

First Valley Medical Group

Lancaster, California, United States

Torrance Clinical Research Institute, Inc.

Lomita, California, United States

Ark Clinical Research

Long Beach, California, United States

Pacific Clinical Studies

Los Alamitos, California, United States

Wetlin Research Associates, Inc.

San Diego, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Encore Medical Research LLC

Hollywood, Florida, United States

Bioclinical Research Alliance

Miami, Florida, United States

South Broward Research LLC

Miramar, Florida, United States

West Orange Endocrinology

Ocoee, Florida, United States

Encore Medical Research of Weston

Weston, Florida, United States

Elite Clinical Trials

Blackfoot, Idaho, United States

Cedar-Crosse Research Center

Chicago, Illinois, United States

Brigham & Women's Hospital

Boston, Massachusetts, United States

Headlands Research

Springfield, Missouri, United States

PharmQuest

Greensboro, North Carolina, United States

Piedmont Healthcare Statesville

Statesville, North Carolina, United States

Providence Center for Clinical Research

Dayton, Ohio, United States

CNS Healthcare

Memphis, Tennessee, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

JCCT- Juno NW Houston

Houston, Texas, United States

Consano Clinical Research, LLC

Shavano Park, Texas, United States

Frontier Clinical Research - Kingwood

Kingwood, West Virginia, United States

Opca bolnica Karlovac

Karlovac, Croatia

Poliklinika SLAVONIJA OSIJEK

Osijek, Croatia

Opca bolnica Varazdin_Endocrinology

Varaždin, Croatia

Poliklinika Solmed

Zagreb, Croatia

Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

Szeged, Csongrád-Csanád, Hungary

Debreceni Egyetem

Debrecen, Hajdú-Bihar, Hungary

Debreceni Egyetem

Debrecen, Hungary

Akaicho Clinic_Internal medicine

Chiba-shi, Chiba, Japan

Naka Kinen Clinic_Internal medicine

Ibaraki, Japan

Soka Sugiura Internal Medicine Clinic

Soka-shi, Saitama, Japan

Tokyo-Eki Center-building Clinic_Internal Medicine

Tokyo, Japan

ToCROM Clinic_Internal Medicine

Tokyo, Japan

"Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik

Bialystok, Podlaskie Voivodeship, Poland

Terpa Sp. z o.o. Sp. k.

Lublin, Poland

Formed 2 Sp. z o.o.

Oświęcim, Poland

PANSTWOWY INSTYTUT MEDYCZNY MSWiA

Warsaw, Poland

Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko

Zabrze, Poland

Casa De Saúde De Santa Filomena S.A._Unidade de Ensaios Clínicos

Coimbra, Portugal

Cardiolima Centro Diagnostico Cardio-Pulmonar De Ponte De Lima Lda

Ponte de Lima, Portugal

Hospital Trofa Saude Senhor do Bonfim S.A_Unidade de Ensaios Clínicos

Vila do Conde, Portugal

Hospital da Luz Arrábida, S.A_Serviço de Endocrinologia

Vila Nova de Gaia, Portugal

DIADA, s.r.o.

Bardejov, Slovakia

Metabol KLINIK s.r.o.

Bratislava, Slovakia

Diacrin s. r. o.

Bratislava, Slovakia

SIN AZUCAR s.r.o.

Malacky, Slovakia

Korea University Ansan Hospital_Endocrinology

Ansan-si, Gyeonggi-do, South Korea

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, South Korea

Nowon Eulji Medical Center, Eulji University_Endocrinology

Seoul, South Korea

Kangbuk Samsung Hospital_Endocrinology

Seoul, South Korea

ABS La Roca CAP Vicenç_Endocrino

La Roca Del Vallés, Barcelona, Spain

Centro de Salud A Estrada

A Estrada, Spain

Equip D´Atencio Primaria Barcelona Sardenya

Barcelona, Spain

Hospital Vithas Sevilla

Castilleja de la Cuesta, Spain

Clínica Bofill

Girona, Spain

Centro de Saúde Concepción Arenal

Santiago de Compostela, Spain

Ramathibodi Hospital

Bangkok, Thailand

Siriraj Hospital

Bangkok, Thailand

Maharaj Nakorn Chiang Mai

Chiang Mai, Thailand

Srinagarind Hospital

Khon Kaen, Thailand

Maharat Nakhon Ratchasima Hospital

Nakhon Ratchasima, Thailand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07415954

Related Trials

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT075901931 location

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

NCT060468331 location

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

NCT07428746

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

NCT072424695 locations

AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes

NCT076226281 location